Performance of FDG PET/ceCT in the evaluation of patients with lung cancer

Biomedicine and Pharmacotherapy

Volumn 68, Issue 2, 2014, Pages 219-223

  Nanni, Cristina ^a   Rossetti, Virginia ^a   Zompatori, Maurizio ^a   Ambrosini, Valentina ^a   Montesi, Valeria ^a   Mascherini, Donatella ^a   Pettinato, Cinzia ^a   Marzola, Maria Cristina ^c   Colletti, Patrick M ^b   Rubello, Domenico ^c   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Santa Maria Misericordia Hospital   (Italy)

Author keywords

FDG PET ceCT; Lung cancer; Performance

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; NEOPLASM; PATIENT SELECTION; PERFORMANCE MEASUREMENT SYSTEM; PHYSICIAN; PRIORITY JOURNAL; RADIOLOGIST; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

FDG PET/CECT; LUNG CANCER; PERFORMANCE;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897034395     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.11.002     Document Type: Article

References (13)

1. Rege S.D., Hoh C.K., Glaspy J.A., Aberle, Dahlbom M., Razavi M.K., et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993, 72:82-90.
2. Yang W., Fu Z., Yu J., Yuan S., Zhang B., Li D., et al. Value of PET/CT versus enhanced CT for loco regional lymph nodes in non small cell lung cancer. Lung Cancer 2008, 61:35-43.
3. Li X., Zhang H., Xing L., Ma H., Xie P., Zhang L., et al. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non small cell lung cancer: a multicenter study. Radiother Oncol 2012, 102:246-250.
4. Gould M.K., Kuschner W.G., Rydzak C.E., Maclean C.C., Demas A.N., Shigemitsu H., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003, 139:879-892.
5. Yun M., Kim W., Alnafisi N., Lacorte L., Jang S., Alavi A. 18F- FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001, 42:1795-1799.
6. Liu N., Ma L., Zhou W., Pang Q., Hu M., Shi F., et al. Bone metastasis in patients with non small cell lung cancer: the diagnostic role of F-18 FDG PET/CT. Eur J Radiol 2010, 74:231-235.
7. Palm I., Hellwig D., Leutz M., Rentz K., Hellwig A., Kirsch C.M., et al. Brain metastases of lung cancer: diagnostic accuracy of positron emission tomography with fluorodeoxyglucose (FDGPET). Med Klin (Munich) 1999, 94:224-227.
8. Posther K.E., Mccall L.M., Harpole D.H., Reed C.E., Putnam J.B., Rusch V.W., et al. Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer. J Nucl Med 2006, 47:1607-1611.
9. Scott W.J., Gobar L.S., Terry J.D., Dewan N.A., Sunderland J.J. Mediastinal lymph node staging of non-small cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996, 111:642-648.
10. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., Dupont P.J., Bogaert J., Maes A., et al. Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998, 16:2142-2149.
11. Pieterman R.M., van Putten J.W., Meuzelaar J.J., et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med 2000, 343:254-261.
12. MacManus M.P., Hicks R.J., Matthews J.P., McKenzie A., Rischin D., Salminen E.K., et al. Positron emission tomography is superior to computed tomography scanning for response- assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 2003, 21:1285-1292.
13. Hicks R.J., Kalff V., Mac Manus M.P., Ware R.E., McKenzie A.F., Mattheus J.P., et al. The utility of (18)F-FDG PET for suspected recurrent non small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001, 42:161-605.